Back to top
more

Vertex Pharmaceuticals (VRTX)

(Delayed Data from NSDQ)

$463.15 USD

463.15
947,949

+1.39 (0.30%)

Updated Sep 26, 2024 04:00 PM ET

Pre-Market: $465.00 +1.85 (0.40%) 9:20 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value F Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (87 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Kodiak Sciences (KOD) Q4 Loss Widens, Eye Candidate in Focus

Kodiak Sciences (KOD) reports a wider-than-expected loss for the fourth quarter of 2021. It is focusing on the lead candidate, KSI-301, being developed for treating various retinal vascular diseases.

FATE's Loss Wider Than Expected in Q4, Pipeline in Focus

FATE reports a wider loss on increased R&D expenses in the fourth quarter.

Endo (ENDP) Surpasses Q4 Earnings and Revenue Estimates

Endo (ENDP) tops Q4 earnings and sales estimates. However, Vasostrict faces generic competition, and the ongoing COVID-19 driven market conditions affect specialty product office-based procedures.

Bayer (BAYRY) Earnings & Revenues Surpass Estimates in Q4

Bayer (BAYRY) beats estimates for both earnings and revenues in the fourth quarter of 2021.

Viatris' (VTRS) Q4 Earnings Miss, Biocon Biologics Deal Inked

Viatris (VTRS) misses on Q4 earnings but surpasses sales estimates. The company announces a combination of its biosimilars portfolio with Biocon Biologics.

VIR Q4 Earnings Beat on Higher Revenues From Covid Treatment

VIR beat earnings estimates in the fourth quarter on higher sotrovimab revenues for COVID-19 patients.

Why Is Vertex (VRTX) Up 0.9% Since Last Earnings Report?

Vertex (VRTX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Radius (RDUS) Q4 Earnings & Revenues Surpass Estimates

Radius (RDUS) beats on earnings and sales in the fourth quarter. The guidance is disappointing.

Aerie (AERI) Q4 Earnings Beat Estimates, Revenues Up Y/Y

Aerie (AERI) beats earnings and sales estimates for the fourth quarter of 2021. AERI's shares increase in the after-market trading session following the news.

Intellia (NTLA) Q4 Loss Wider Than Expected, Revenues Up Y/Y

Intellia Therapeutics (NTLA) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.

Agios (AGIO) Loss Wider Than Expected in Q4, Revenues Nil

Agios Pharmaceuticals (AGIO) posts wider-than-expected loss for the fourth quarter of 2021. It does not record any revenues in the quarter.

Theravance's (TBPH) Q4 Earnings and Sales Miss Estimates

Theravance (TBPH) reports wider-than-expected loss for the fourth quarter of 2021. Revenues decline year over year.

Arena (ARNA) Q4 Loss Wider Than Expected, Etrasimod in Focus

Arena Pharmaceuticals (ARNA) misses on Q4 bottom line. Top-line data from several phase III studies on etrasimod are slated for release in 2022.

Clovis (CLVS) Q4 Loss Narrower than Expected, Revenues Lag

Clovis (CLVS) reports narrower-than-expected loss for fourth-quarter 2021. Sales of the sole marketed drug Rubraca decline year over year due to COVID-19 impacts.

Moderna (MRNA) Q4 Earnings Top, COVID-19 Vaccine Brings $7B

Moderna's (MRNA) COVID-19 vaccine sales beat expectations. The company delivers 297 million doses of its COVID-19 vaccine during the fourth quarter. Stock gains in pre-market.

BioMarin (BMRN) Q4 Earnings Top Estimates, Sales Fall Y/Y

Biomarin Pharmaceutical's (BMRN) fourth-quarter earnings and sales beat estimates. Stock declines

Bausch's (BHC) Q4 Earnings Beat Estimates, Revenues Miss

Bausch (BHC) beats on earnings but misses on sales in the fourth quarter. The outlook for 2022 is disappointing.

AstraZeneca (AZN) Enhertu Effective in HER2-Low Breast Cancer

AstraZeneca's (AZN) DESTINY-Breast04 is the first-ever phase III study of a HER2-directed therapy to show a statistically significant and clinically meaningful survival benefit in patients with HER2-low metastatic breast cancer.

Should Value Investors Pick Vertex Pharmaceuticals (VRTX) Stock?

Let's see if Vertex Pharmaceuticals Incorporated (VRTX) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.

Agios (AGIO) Gets FDA Nod for Rare Anemia Drug Mitapivat

Agios Pharmaceuticals' (AGIO) Pyrukynd (mitapivat) is the first disease-modifying therapy approved to treat PK deficiency, a rare, debilitating, blood disorder.

Repligen (RGEN) Q4 Earnings and Revenues Surpass Estimates

Repligen's (RGEN) fourth-quarter earnings and revenues beat estimates. It expects to achieve revenue growth in the range of 19-24% in 2022.

Sage Therapeutics (SAGE) Depression Drug Meets Goal, Stock Down

Sage Therapeutics (SAGE) and Biogen's (BIIB) depression candidate, zuranolone given along with antidepressants improves depressive symptoms in a phase III study. Questions remain about the durability of the drug.

AstraZeneca's (AZN) Lupus Drug Saphnelo Gets Europe Nod

AstraZeneca's (AZN) Saphnelo is the only new biologic to be approved in Europe in over a decade for patients with systemic lupus erythematosus.

Intellia (NTLA) Up on Deal With ONK for Cancer Therapies

Intellia (NTLA) partners with ONK Therapeutics. The collaboration utilises their respective proprietary platforms to develop allogeneic CRISPR-based NK cell therapies for the treatment of cancer.

CRISPR Therapeutics (CRSP) Q4 Earnings Miss, Revenues Up Y/Y

CRISPR Therapeutics (CRSP) reports wider-than-expected Q4 loss. Nonetheless, revenues beat estimates.